TITLE

The aspirin question

PUB. DATE
June 2013
SOURCE
Consumer Reports on Health;Jun2013, Vol. 25 Issue 6, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the prevalence of heart attacks and strokes among U.S. consumers and discusses the role that a low dose aspirin regimen can play in preventing heart attacks and strokes. A discussion of medical complications which can be associated with aspirin, and of aspirin alternatives and add-ons which are available to prevent the complications, is presented. INSETS: Aspirin alternatives and add-ons;Resistance to aspirin?.
ACCESSION #
87761825

 

Related Articles

  • Clopidogrel in ischemic heart disease: A critical appraisal. Al-Otaiby, Mohammed A.; Al-Moghairi, Abdulrahman M. // Health (1949-4998);Mar2013, Vol. 5 Issue 3, p465 

    Aspirin and clopidogrel are the commonest dual antiplatelet agents being used in the secondary prevention of cardiovascular disease. In high risk patients with coronary heart disease, the use of aspirin was associated with a significant risk reduction of myocardial infarction, stroke and...

  • Potential Interaction between Clopidogrel and Proton Pump Inhibitors. Howard, Patricia A.; Vacek, James L. // American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353 

    Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with...

  • Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. Douglas, Ian J.; Evans, Stephen J. W.; Hingorani, Aroon D.; Grosso, Anthony M.; Timmis, Adam; Hemingway, Harry; Smeeth, Liam // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/11/2012, Vol. 345 Issue 7869, p15 

    The article reports on research which was conducted to determine whether pharmacokinetic interaction between proton pump inhibitors and clopidogrel lead to harmful vascular events. A comparison between cohort and within person study designs was carried out as part of the research. The results...

  • Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Oyetayo, O.O.; Farris, C.A.; Wahawisan, J. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p9 

    Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI...

  • ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use Abraham, Neena S; Hlatky, Mark A; Antman, Elliott M; Bhatt, Deepak L; Bjorkman, David J; Clark, Craig B; Furberg, Curt D; Johnson, David A; Kahi, Charles J; Laine, Loren; Mahaffey, Kenneth W; Quigley, Eamonn M; Scheiman, James; Sperling, Laurence S; Tomaselli, Gordon F // American Journal of Gastroenterology;Dec2010, Vol. 105 Issue 12, p2533 

    The article discusses the use of proton pump inhibitors (PPI) and thienopyridines as an alternative treatment for cardiovascular (CV) diseases. It says that clopidogrel is more effective than aspirin in reducing main CV events. It mentions the greater risk for gastrointestinal (GI) bleeding in...

  • Could recommendations about aspirin prophylaxis enhance colorectal cancer screening programmes? Morgan, Gareth; Elwood, Peter // European Journal of Public Health;Dec2009, Vol. 19 Issue 6, p576 

    The article analyzes a study which examined the effectiveness of aspirin prophylaxis in enhancing colorectal cancer screening programmes. The health benefits of aspirin are noted, including reducing the risk of vascular events and myocardial infarction. The study observed that the benefits of...

  • Management of nonvariceal upper gastrointestinal bleeding. Wee, E. // Journal of Postgraduate Medicine;Apr-Jun2011, Vol. 57 Issue 2, p161 

    Nonvariceal upper gastrointestinal bleeding is unique from variceal bleeding in terms of patient characteristics, management, rebleeding rates, and prognosis, and should be managed differently. The majority of nonvariceal upper gastrointestinal bleeds will not rebleed once treated successfully....

  • Clopidogrel plus proton pump inhibitor linked with increased risk for rehospitalization.  // Hem/Onc Today;5/25/2010, Vol. 11 Issue 10, p8 

    The article discusses the study about the impact of taking clopidrogel combined with proton pump inhibitor on risk for rehospitalization following a myocardial infarction or stent placement by researchers from Irvine, California and Seattle.

  • Advances in Our Understanding of ''Resistance'' to Antiplatelet Agents for Prevention of Ischemic Stroke. Gorelick, Philip B.; Farooq, Muhammad U. // Stroke Research & Treatment;2013, p1 

    We review the role of aspirin and clopidogrel for prevention of ischemic stroke and explore the concept of antiplatelet therapy resistance both from a laboratory and clinical perspective and genetic polymorphisms that might influence platelet reactivity with clopidogrel administration. Debates...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics